TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20155991

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg with simultaneous discontinuation of the current antipsychotic
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg with tapering off the current antipsychotic over 4 weeks with half the dose after the first 2 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg with tapering off the current antipsychotic over 4 weeks after maintenance of the current dose for 2 weeks
Number of subjects: 77
Study: 17506781

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg at night
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 15945343

Group type: EXPERIMENTAL
Intervention: docetaxel (Taxotere) plus estramustine (Emcyt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: docetaxel given every 3 weeks plus prednisone
Number of subjects: 0
Study: 11842036

Group type: EXPERIMENTAL
Intervention: 23.5 degrees C exposure in C
Number of subjects: 12

Group type: COMPARATOR
Intervention: 23.5 degrees C exposure in N
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fingertip temperature in C
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fingertip temperature in N
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cold discomfort rating in C
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cold discomfort rating in N
Number of subjects: 12
Study: 10421111

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (> 35 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hypothermic CPB (30 degrees C)
Number of subjects: 30
Study: 7767514

Group type: EXPERIMENTAL
Intervention: ICI 204,219 20 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ICI 204,219 40 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ICI 204,219 10 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ICI 204,219 100 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 2082945

Group type: COMPARATOR
Intervention: Nitroprusside infusion (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Labetalol bolus injections of 10 mg every 10 min (n = 10)
Number of subjects: 20
Study: 7417129

Group type: EXPERIMENTAL
Intervention: +3Gz acceleration stress
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: +5Gz acceleration stress
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: +7Gz acceleration stress
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall VCG changes during +Gz stress
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-exposure to +Gz stress
Number of subjects: 10
Study: 30635141

Group type: EXPERIMENTAL
Intervention: Enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day)
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Sucrose (same dose as lactoferrin)
Number of subjects: 2203
Study: 27844278

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 361
Study: 27052031

Group type: EXPERIMENTAL
Intervention: Incident Atrial Fibrillation (AF)
Number of subjects: 2753
Study: 25225565

Group type: EXPERIMENTAL
Intervention: Filmed modeling
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tell‐Show‐Do technique (T.S.D)
Number of subjects: 46
Study: 21728445

Group type: EXPERIMENTAL
Intervention: Mortality salience (MS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 19400488

Group type: EXPERIMENTAL
Intervention: Intraoperative ketamine infusion combined with spinal anaesthesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo combined with spinal anaesthesia
Number of subjects: 12
Study: 17953336

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 15 microg of fentanyl (Group 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 25 microg of fentanyl (Group 3)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bupivacaine (Group 1)
Number of subjects: 75
Study: 16034041

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC)
Number of subjects: 405
Study: 11997817

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Toupet procedure
Number of subjects: 200
Study: 10077414

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem-SR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All drugs (when baseline heart rate ≤ 65 beats/min)
Number of subjects: 0
Study: 7536623

Group type: EXPERIMENTAL
Intervention: GAGPS (25 mg, 0.5 ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GAGPS
Number of subjects: 80
Study: 2044393

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscularly up to 4-times a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Buprenorphine 0.3 mg intramuscularly up to 4-times a day
Number of subjects: 60
Study: 7195748

Group type: EXPERIMENTAL
Intervention: Cisplatin administration
Number of subjects: 0
Study: 31914474

Group type: EXPERIMENTAL
Intervention: Large midbody MTL disruption
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Corresponding PMM tears
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repair of each lesion (MTL and PMM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ACL-deficient knees with MTL and PMM lesions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repair of meniscal lesions alone in ACL-deficient knees
Number of subjects: 12
Study: 30262813

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Heat‐killed Bifidobacterium animalis subsp. lactis CECT 8145 (h‐k Ba8145)
Number of subjects: 135
Study: 29584910

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (n=98)
Number of subjects: 195

Group type: COMPARATOR
Intervention: EFV/FTC/TDF (n=97)
Number of subjects: 195
Study: 27884851

Group type: EXPERIMENTAL
Intervention: RIC+pPCI
Number of subjects: 139

Group type: COMPARATOR
Intervention: pPCI alone
Number of subjects: 139
Study: 25070483

Group type: EXPERIMENTAL
Intervention: Structured, low‐glycemic portion‐controlled diet (PCD) intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual dietary care (UDC)
Number of subjects: 73
Study: 22515880

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mix
Number of subjects: 100

Group type: COMPARATOR
Intervention: Room air/oxygen mix (placebo)
Number of subjects: 100
Study: 18562399

Group type: EXPERIMENTAL
Intervention: Exact methods for meta-analyses of safety data
Number of subjects: 700

Group type: COMPARATOR
Intervention: Asymptotic methods for meta-analyses of safety data
Number of subjects: 700
Study: 17633370

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine for supporting healthy energy and strengthening Pi, additional to chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 60
Study: 15326194

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin-based)
Number of subjects: 5716

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (single-agent UFT)
Number of subjects: 5716

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 5716
Study: 12399205

Group type: EXPERIMENTAL
Intervention: Regular-dose regimen (5 micro g)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Reduced-dose regimen (2.5 micro g)
Number of subjects: 574
Study: 11251757

Group type: EXPERIMENTAL
Intervention: Medication grid intervention
Number of subjects: 836

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 836
Study: 9272813

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 7

Group type: COMPARATOR
Intervention: Significant nerve injury
Number of subjects: 7
Study: 7944415

Group type: EXPERIMENTAL
Intervention: Transcatheter immunoembolization (TIE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Transcatheter arterial embolization (TAE)
Number of subjects: 14
Study: 2974428

Group type: EXPERIMENTAL
Intervention: Danazol (200 mg three times a day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA, 100 mg a day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ovarian endometriosis
Number of subjects: 49
Study: 1426844

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA solution administered per os or per rectum at a concentration of 1 mmol/L
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA solution
Number of subjects: 31

Group type: COMPARATOR
Intervention: Plain MR
Number of subjects: 31

Group type: COMPARATOR
Intervention: CT
Number of subjects: 31
Study: 71447

Group type: EXPERIMENTAL
Intervention: Leucocyte-migration-inhibition tests (L.M.T.) against breast-cancer antigen
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Family history of breast cancer and/or previous surgery for cystic and proliferative disease
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined presence of epidemiological risk factors and an abnormal mammogram
Number of subjects: 62
Study: 30353262

Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine infusion (0.5 mg/kg over 40 min)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30669411

Group type: EXPERIMENTAL
Intervention: Wheat Albumin (WA) 1.5 g
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 30173449

Group type: EXPERIMENTAL
Intervention: № I Empirical Prescription for Chronic Prostatitis (1 dose per day for 8 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saw palmetto extract (160 mg bid for 8 weeks)
Number of subjects: 53
Study: 26766797

Group type: EXPERIMENTAL
Intervention: Laser lithotripter
Number of subjects: 77

Group type: COMPARATOR
Intervention: Ultrasonic lithotripter
Number of subjects: 77
Study: 24986217

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 14099

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14099
Study: 22569025

Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 411

Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Remifentanil groups
Number of subjects: 411
Study: 19171291

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (education)
Number of subjects: 0
Study: 17991258

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 microg.kg(‐1)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 microg.kg(‐1)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 510
Study: 15718317

Group type: EXPERIMENTAL
Intervention: 30 Gy/15 fractions during 3 weeks
Number of subjects: 625

Group type: COMPARATOR
Intervention: 20 Gy/10 fractions over 2 weeks
Number of subjects: 625
Study: 12010273

Group type: EXPERIMENTAL
Intervention: Insyte AutoGuard
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Protective Acuvance
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional catheter needle (Insyte)
Number of subjects: 300
Study: 10464781

Group type: COMPARATOR
Intervention: SF-bread
Number of subjects: 18
Study: 7818111

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms/kg IV
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clonidine 6 micrograms/kg IV
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg IV
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2112187

Group type: EXPERIMENTAL
Intervention: R‐ORS + SF
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: G‐ORS + RF
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: G‐ORS + rice
Number of subjects: 200

Group type: COMPARATOR
Intervention: G‐ORS + SF
Number of subjects: 200
Study: 465279

Group type: EXPERIMENTAL
Intervention: Atenolol 4%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adrenaline 1%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined treatment with atenolol and adrenaline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 14
Study: 30590556

Group type: EXPERIMENTAL
Intervention: Health behaviours perceived as generating enduring and fundamental benefits
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Drugs with enduring benefits
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Future clarity measure
Number of subjects: 242
Study: 31550810

Group type: EXPERIMENTAL
Intervention: Tailored quadruple therapy based on clarithromycin sensitivity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving clarithromycin quadruple therapy (PPI, amoxicillin, clarithromycin, bismuth)
Number of subjects: 0
Study: 28755406

Group type: EXPERIMENTAL
Intervention: 300 mg apple polyphenols for 8 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 62
Study: 26451235

Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hyperferritinemia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Iron intake
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome risk factors
Number of subjects: 66
Study: 23557482

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention consisting of up to six face-to-face counseling sessions with a trained practice nurse, followed by three-monthly sessions by phone.
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 622

Group type: COMPARATOR
Intervention: Control group (health brochures)
Number of subjects: 622
Study: 21538030

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg daily for 8 weeks
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 175
Study: 20104156

Group type: EXPERIMENTAL
Intervention: Osteochondral autologous transplantation (OAT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OAT
Number of subjects: 50

Group type: COMPARATOR
Intervention: MF
Number of subjects: 50
Study: 17328057

Group type: EXPERIMENTAL
Intervention: Onercept 100 mg
Number of subjects: 127
Study: 15316583

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei fermented milk (108 ‐ 1010/g), 3 cups per day for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11952581

Group type: EXPERIMENTAL
Intervention: Day surgery
Number of subjects: 100
Study: 9481553

Group type: EXPERIMENTAL
Intervention: Day case surgery
Number of subjects: 194

Group type: COMPARATOR
Intervention: In-patient admission
Number of subjects: 194

Group type: COMPARATOR
Intervention: Non-randomised in-patient group
Number of subjects: 194
Study: 7612535

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g four times daily on days 1 to 4 for two cycles)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Norethisterone (5 mg twice a day on days 19 and 26 for two cycles)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 2653386

Group type: EXPERIMENTAL
Intervention: L-DOPA and 5 HTP in small doses
Number of subjects: 17

Group type: COMPARATOR
Intervention: R-tetrahydrobiopterin (R-THBP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 17
Study: 792398

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 29549588

Group type: EXPERIMENTAL
Intervention: Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel (A0.3/BPO2.5)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 67
Study: 27028749

Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg + Indacaterol (IND) 150 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropinium (TIO) 18 mcg + Indacaterol (IND) 150 mcg
Number of subjects: 0
Study: 24674732

Group type: EXPERIMENTAL
Intervention: Topical application of Evicel (fibrin sealant)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 62
Study: 22331237

Group type: EXPERIMENTAL
Intervention: Concomitant NP (vinorelbine and cisplatin) and Rh-endostatin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single NP (vinorelbine and cisplatin)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rh-endostatin followed by NP
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rh-endostatin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined therapy (concomitant NP and Rh-endostatin)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rh-endostatin combined with chemotherapy
Number of subjects: 72
Study: 20798023

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity programme (9 weeks, 60 minutes per session)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Health behaviour education sessions (control group)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity programme (9 weeks)
Number of subjects: 481
Study: 17356003

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RTE)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No intervention (C)
Number of subjects: 180
Study: 16381266

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.15%; 15 mg) + Fentanyl (0.0002%; 2 microg/ml) + Epinephrine (1.7 microg/ml; 1:600,000)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine (0.15%; 15 mg) + Fentanyl (0.0002%; 2 microg/ml)
Number of subjects: 50
Study: 11912423

Group type: EXPERIMENTAL
Intervention: Outpatient/clinic based setting
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inpatient/operative setting
Number of subjects: 25
Study: 9798343

Group type: COMPARATOR
Intervention: HLA-Cw1
Number of subjects: 26

Group type: COMPARATOR
Intervention: HLA-B46
Number of subjects: 26

Group type: COMPARATOR
Intervention: HLA-DQB1*0303
Number of subjects: 26
Study: 8561257

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 300 mg weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study: 2539655

Group type: EXPERIMENTAL
Intervention: Etoposide 300 mg/m2 for two days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Combination of vincristine 1 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 1000 mg/m2 (VAC)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 103

Group type: COMPARATOR
Intervention: Combination chemotherapy (VAC)
Number of subjects: 103
Study: 71973

Group type: EXPERIMENTAL
Intervention: 200 mg flurbiprofen daily for 2 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin daily for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo washout period
Number of subjects: 30
Study: 30745014

Group type: EXPERIMENTAL
Intervention: Furosemide (in-hospital dose)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Furosemide utilisation relative to baseline
Number of subjects: 430

Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 430
Study: 31290727

Group type: EXPERIMENTAL
Intervention: PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes (PD-miOXNP)
Number of subjects: 0
Study: 27792019

Group type: EXPERIMENTAL
Intervention: Task-oriented electromyography-triggered stimulation for 30 minutes, five times a week for four weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclic functional electrical stimulation for 30 minutes, five times a week for four weeks
Number of subjects: 20
Study: 25731736

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 23011843

Group type: EXPERIMENTAL
Intervention: Bupivacaine (300 mL of 0.5% bupivacaine)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline (300 mL of 0.9% normal saline solution)
Number of subjects: 150
Study: 21742399

Group type: EXPERIMENTAL
Intervention: Telmisartan (group T)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Amlodipine (group A)
Number of subjects: 81
Study: 18081859

Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD) + low-level laser therapy (LLLT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Enamel matrix protein derivative (EMD)
Number of subjects: 22
Study: 16977952

Group type: EXPERIMENTAL
Intervention: Propex apex locator
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Raypex-4 apex locator
Number of subjects: 100
Study: 12711730

Group type: EXPERIMENTAL
Intervention: Partners in Caregiving intervention (communication and conflict resolution training)
Number of subjects: 1587
Study: 11084267

Group type: EXPERIMENTAL
Intervention: Nonmechanical trephination (NMT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mechanical trephination (MT)
Number of subjects: 96
Study: 9366727

Group type: EXPERIMENTAL
Intervention: Specialist community rehabilitation for up to 3 months after randomisation
Number of subjects: 331

Group type: COMPARATOR
Intervention: Conventional hospital and community care
Number of subjects: 331
Study: 10136097

Group type: EXPERIMENTAL
Intervention: Appointment reminder postcards for 2 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Appointment reminder phone calls for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention for 2 weeks
Number of subjects: 10
Study: 3110307

Group type: EXPERIMENTAL
Intervention: Immune serum gamma globulin (ISG) 5 or 10 ml
Number of subjects: 107803

Group type: EXPERIMENTAL
Intervention: Immune serum gamma globulin (ISG) 2 ml
Number of subjects: 107803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107803